Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim announces SMC acceptance of Pradaxa

Boehringer Ingelheim announces SMC acceptance of Pradaxa

11th June 2008

Boehringer Ingelheim has announced that the Scottis Medicines Consortium (SMC) has accepted novel orally-administered anticoagulant Pradaxa (dabigatran etexilate) for routine use within the NHS in Scotland.

The compound previously was granted marketing authorisation by the European Commission in March 2008.

In addition to the decision by the SMC, the Danish Institute for Rational Pharmacotherapy belonging to the Danish Medicines Agency has given its endorsement to Pradaxa as a good alternative to low molecular weight heparins.

Pradaxa prevents thrombus formation through the specific and selective inhibition of thrombin, which is the main enzyme in the coagulation cascade that facilitates the conversion of fibrinogen into fibrin.

Simon Frostick, professor of orthopaedics at the University of Liverpool, said: “With Pradaxa as a new therapeutic option, we have an effective oral, once-daily anticoagulant with a good efficacy and safety profile to facilitate convenient thromboprophylaxis both in and out of hospital.”

He added that thromboprophylaxis after orthopaedic surgery is vital for the protection of patients from thrombi that can be potentially life-threatening.

Pradaxa was launched in the UK in April 2008 after it was approved by the European Commission in the previous months following the submission of clinical trial data from the Re-Model and Re-Novate trials.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.